STH Biotech
Description
STH BIOTECH develops SATIVITRO®, a unique biotech platform for the production of rare compounds in plants. Through metabolic engineering and the cultivation of transformed roots into bioreactors, we unlock access to these rare molecules. Our technology enables to increase the yield of target molecules by up to 1000 times, while ensuring quality and consistency that perfectly meet pharmaceutical standards.
Our first case study? Cannabinoids—molecules which could be game-changing treatments for medical conditions like glaucoma, chronic pain, or epilepsy, currently affecting over 50M Europeans. Starting with a 1st ingredient for the cosmetics market in 2025, we will use this growth lever to secure the development of +50 molecules and successfully target the biopharma industry within the next 5 years.
